Some Journals considers all the manuscripts submissions as a basis of acceptance rate computation. Basic Journal Info Country China Journal ISSN: 26172216 Publisher: AME Publishing Company History: 2018-2021 Journal Hompage: Link How to Get Published: Find out more Research Categories Biochemistry, Genetics and Molecular Biology Precision Cancer Medicine Impact Factor by Web of Science Index Citations. Article Processing Charges - Precision Cancer Medicine This approach uses T-cell receptor (TCR) engineered T-cells, and involves retroviruses that enable integration of new TCR transgene targeting antigens, which are expressed at high levels on different cancers into the genome of T-cells.98 TCR therapy has been assessed in hematologic and solid malignancies.99103 Current trials evaluate treatment-associated toxicity, binding affinity to tumor antigens and efficacy in carefully selected patients with increased tumor burden. Transcriptomics are utilized to identify prognostic and predictive gene expression signatures50,51, to explore miRNAs and their role in mRNA regulation52,53 and to identify the tissue of origin in cancer of unknown primary.5456 The first solid tumor precision medicine trial to use transcriptomics in the clinic--WINTHER---compared RNA expression in tumors to that in adjacent normal tissue and demonstrated that transcriptomics increased the number of patients that could be matched to therapy.13 Comparing tumor to normal tissue from the same patient may be necessary because of the large inter-patient variability in normal RNA expression. From precision medicine to precision care: Choosing and using precision medicine in the context of multimorbidity. We are pleased to announce that the Translational Cancer Research (TCR) has attained its latest impact factor update for the 2021 citation year: 0.496. A multidisciplinary journal which advances our medical knowledge. Correct assessment of a genetic variant relies on the clinical context and knowledge of the underlying bio Profiling the somatic mutations of genes which may inform about tumor evolution, prognostics and treatment is becoming a standard tool in clinical oncology. However, certain high-risk cohorts, such as patients with MYCN-amplified neuroblas Glioblastoma multiforme (GBM) constitutes nearly half of all malignant brain tumors and has a median survival of 15months. Huang GD, Bull J, Johnston McKee K, Mahon E, Harper B, Roberts JN. Seminars JCO Precision Oncology - Impact Factor & Score 2023 - Research.com Universities and research institutions in China
official website and that any information you provide is encrypted Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden, Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma, PBRM1 loss promotes tumour response to immunotherapy, Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors, OA04.05 KEYNOTE-021: TMB and Outcomes for Carboplatin and Pemetrexed With or Without Pembrolizumab for Nonsquamous NSCLC. Top Journals in Cancer Research - Resurchify Before ISSN 0028-0836 (print). Autologous cells are being harvested and administered to patients after their expansion and activation. Cancer Medicine - Wiley Online Library sharing sensitive information, make sure youre on a federal It is based on the idea that 'all citations are not created equal'. The overall rank of Precision Cancer Medicine is 17687 . Long GV, Stroyakovskiy D, Gogas H, et al. ESMO Open: First Official Impact Factor of 5.329 The two years line is equivalent to journal impact factor (Thomson . Browse Journal. 1. The journal publishes basic and clinical trials studies which aim to promote personalized medicine, including novel technologies of cancer diagnosis, new drugs and . Only Open Access Journals Only SciELO Journals Only WoS Journals Results 3.1. Cambridge Prisms: Precision Medicine | Cambridge Core Despite the significant benefit noted in patients with diverse tumor types treated with checkpoint inhibitors, approximately 80% of patients across cancers do not experience beneficial effects. Bethesda, MD 20894, Web Policies Dr. Apostolia-Maria Tsimberidou has the following financial relationships to disclose: Research Funding (Institution): Immatics, Parker Institute for Cancer Immunotherapy, Tempus, OBI Pharma, EMD Serono, Baxalta, ONYX, Bayer, Boston Biomedical, Placon Therapeutics, Karus Therapeutics, and Tvardi Therapeutics. Editorial Team - Precision Cancer Medicine This collection of articles has not been sponsored and articles have undergone the journals standard peer-review process. Precision cancer medicine - biomedcentral.com Translational Cancer Research (Transl Cancer Res, TCR; Print ISSN: 2218-676X; Online ISSN 2219-6803) is an Open Access, peer-reviewed journal, indexed in Science Citation . and JavaScript. . Please refer to the Web of Science data source to check the exact journal impact factor (Thomson Reuters) metric. This complexity is attributed to highly variable patterns of genetic and epigenetic diversity and clonal architecture associated with spatial expansion, proliferative self-renewal, migration, and invasion. Published online by Cambridge University Press. CAR T-cells are a type of adoptive T-cell therapy in which autologous T-lymphocytes are genetically engineered to recognize the antigens expressed on malignant cells.95 Adoptive T-cell therapy has resulted in remarkably high rates of durable CR in hematologic malignancies, including in patients with refractory disease. Kobayashi S, Boggon TJ, Dayaram T, et al. SJR acts as an alternative to the Journal Impact Factor (or an average number of citations received in last 2 years). Consulting or Advisory Role: Covance, Genentech, and Tempus. Directory of Open Access Journals (DOAJ) Colorectal Cancer. Currently, genomics is the main factor influencing precision medicine in oncology. Precision Cancer Medicine (PCM, Precis Cancer Med, ISSN: 2617-2216) is an open access, peer-reviewed online journal dedicated to precise diagnosis and treatment of cancers and personalized care for patients. Journal Metrics: Cancer Medicine. JCO Precision Oncology showcases high-quality, original documents where all submitted articles are peer reviewed . Cancer Medicine Key Factor Analysis. Precision medicine (PM) can be defined as a predictive, preventive, personalized, and participatory healthcare service delivery model. 20206 three and four years have been cited in the current year. About | Precision Clinical Medicine | Oxford Academic statement and The ultimate goal of precision medicine is an individualized, patient-centered (rather than drug-centered) trial based on the best available biomarkers. The format of this category is recommended as follows: Introduction, Case Presentation, Tumor Management, Case-related Literature Review and Conclusion. Precision oncology - Nature The clinical integration of genome sequencing into standard clinical practice has b Comprehensive genomic sequencing (CGS) has the potential to revolutionize precision medicine for cancer patients across the globe. Furthermore, metastatic tumors harbor tremendously complex and individually unique genomic and immune landscapes.22,23 Therefore, in order to target malignancies with precision, treatment needs to be personalized. Researchers may also consider the practical aspect of a journal such as publication fees, acceptance rate, review speed. Tumor and cell-free DNA profiling, immune markers, and proteomic and RNA analyses are used to identify these characteristics for optimization of anticancer therapy in individual patients. Cristofanilli M, Budd GT, Ellis MJ, et al. Get the most important science stories of the day, free in your inbox. . Nature Portfolio. We are pleased to present the 2022 Annual Report of Precision Cancer Medicine (PCM). 152OFirst report of AURORA, the breast international group (BIG) molecular screening initiative for metastatic breast cancer (MBC) patients (pts), Signature program: a platform of basket trials, Personalized antibodies for gastroesophageal adenocarcinoma (PANGEA): A phase II precision medicine trial (NCT02213289). Indexing - Future Medicine Data Source: Scopus, Explore, visually communicate and make sense of data with our, Metrics based on Scopus data as of April 2023, Biochemistry, Genetics and Molecular Biology. SCIMAGO SJR: 2.116. Govers C, Sebestyn Z, Coccoris M, Willemsen RA, Debets R. T cell receptor gene therapy: strategies for optimizing transgenic TCR pairing, Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Postdoctoral Research Fellow at the Dalian Institute of Chemical Physics, Professor/Associate Professor/Assistant Professor/Senior Lecturer/Lecturer, Faculty Positions at SUSTech Department of Biomedical Engineering. Molecularly targeted agents aim to Homologous recombination (HR) is the primary pathway for repairing double-strand DNA breaks implicating in the development of cancer. AR-V7 and treatment selection in advanced prostate cancer: are we there yet? Besser MJ, Shapira-Frommer R, Itzhaki O, et al. Specific guidelines of this series could be found in the Author Instructions. In recent years, biotechnological breakthroughs have led to identification of complex and unique biologic features associated with carcinogenesis. You can start . Genome Medicine 2016 8 :108. The stunning possibility exists that real-world data, if confirmed to accurately portray the anticipated results of prospective trials, will dramatically accelerate the drug approval process. According to SCImago Journal Rank (SJR), this journal is ranked 0.219. Precision oncology has tended to focus on the cancer genome, but also taking into account RNA and proteins, for example, could identify new options for targeted treatments. As there are several TKIs, upon progression, the optimal sequential ALK and ROS-1 TKI strategy at progression is relevant, and this may have an impact on patients' outcome. The investigators demonstrated that CTC monitoring was a robust and meaningful response endpoint for early-phase clinical trials in this setting.49. Neoplastic reprogramming of patient-derived adipose stem cells by prostate cancer cell-associated exosomes. Beyond genomics, RNA and protein profiling, with proteins being the effectors of signaling, also appear to be important in mediating biologic impact. 1The University of Texas MD Anderson Cancer Center, Department of Investigational Cancer Therapeutics, Houston, TX, 2Department of Medical Oncology, Euromedica General Clinic, Thessaloniki, Greece, 3Center for Personalized Cancer Therapy and Division of Hematology and Oncology, UC San Diego Moores Cancer Center, San Diego, CA, USA. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma, Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children, Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers, PD-1 Blockade in Tumors with Mismatch-Repair Deficiency, The Marriage Between Genomics and Immunotherapy: Mismatch Meets Its Match, A novel c-abl protein product in Philadelphia-positive acute lymphoblastic leukaemia, The molecular genetics of Philadelphia chromosome-positive leukemias, Lung Master Protocol (Lung-MAP)-A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400, Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients. Precision Cancer Medicine - SCI Journal